Incyte Co. (NASDAQ:INCY) had its price objective lowered by stock analysts at Barclays PLC from $185.00 to $180.00 in a report issued on Wednesday. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays PLC’s price objective suggests a potential upside of 46.21% from the stock’s current price.

INCY has been the subject of several other research reports. Cowen and Company reiterated an “outperform” rating on shares of Incyte in a research report on Thursday, January 12th. Goldman Sachs Group Inc increased their price objective on shares of Incyte from $116.00 to $149.00 and gave the company a “buy” rating in a research report on Friday, January 27th. Nomura started coverage on shares of Incyte in a report on Wednesday, March 1st. They issued a “buy” rating for the company. Royal Bank of Canada raised their target price on shares of Incyte from $123.00 to $138.00 and gave the stock an “outperform” rating in a report on Wednesday, February 15th. Finally, JMP Securities restated an “outperform” rating and issued a $130.00 target price on shares of Incyte in a report on Wednesday, January 18th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Incyte presently has an average rating of “Buy” and an average price target of $139.40.

Analyst Recommendations for Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) traded down 1.15% during mid-day trading on Wednesday, hitting $123.11. 2,034,400 shares of the stock were exchanged. Incyte has a 52 week low of $68.03 and a 52 week high of $153.15. The company has a 50-day moving average of $139.05 and a 200-day moving average of $114.33. The stock has a market capitalization of $23.32 billion, a PE ratio of 227.98 and a beta of 0.78.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, February 14th. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by $0.09. Incyte had a net margin of 14.71% and a return on equity of 50.38%. The business had revenue of $326 million for the quarter, compared to the consensus estimate of $324.90 million. During the same quarter last year, the business earned $0.29 EPS. Incyte’s revenue for the quarter was up 33.9% compared to the same quarter last year. On average, equities analysts predict that Incyte will post $0.18 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Incyte Co. (INCY) Given New $180.00 Price Target at Barclays PLC” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at http://www.watchlistnews.com/barclays-plc-reaffirms-overweight-rating-for-incyte-co-incy/1202962.html.

In other news, Director Jean Jacques Bienaime acquired 1,000 shares of the business’s stock in a transaction dated Friday, April 7th. The shares were purchased at an average price of $139.48 per share, with a total value of $139,480.00. Following the transaction, the director now directly owns 2,177 shares in the company, valued at $303,647.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Steven H. Stein sold 32,000 shares of Incyte stock in a transaction that occurred on Friday, April 7th. The stock was sold at an average price of $137.88, for a total transaction of $4,412,160.00. Following the completion of the transaction, the executive vice president now directly owns 41,648 shares in the company, valued at approximately $5,742,426.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 127,571 shares of company stock worth $18,145,772. Insiders own 13.70% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Asymmetry Capital Management L.P. increased its position in shares of Incyte by 46.6% in the third quarter. Asymmetry Capital Management L.P. now owns 37,407 shares of the biopharmaceutical company’s stock worth $3,527,000 after buying an additional 11,897 shares during the last quarter. NF Trinity Capital Hong Kong Ltd purchased a new position in shares of Incyte during the third quarter worth about $7,072,000. Jana Partners LLC purchased a new position in shares of Incyte during the third quarter worth about $5,505,000. Blue Jay Capital Management LLC purchased a new position in shares of Incyte during the third quarter worth about $12,085,000. Finally, Frontier Capital Management Co. LLC increased its position in shares of Incyte by 8.9% in the fourth quarter. Frontier Capital Management Co. LLC now owns 1,104,616 shares of the biopharmaceutical company’s stock worth $110,760,000 after buying an additional 90,098 shares during the last quarter. 92.62% of the stock is currently owned by hedge funds and other institutional investors.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

5 Day Chart for NASDAQ:INCY

Receive News & Ratings for Incyte Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.